Diflunisal

證據等級: L5

預測適應症: 10 個

Diflunisal: From Analgesic Use to Ankylosing Spondylitis

One-Sentence Summary

Diflunisal is a difluorophenyl derivative of salicylic acid in the NSAID class, historically used for mild-to-moderate pain relief and musculoskeletal inflammation. The TxGNN model predicts it may be effective for Ankylosing Spondylitis — the highest-evidence prediction among all candidates — with 0 clinical trials and 7 publications supporting this direction, including a 1986 double-blind controlled trial comparing diflunisal directly against phenylbutazone in AS patients.

Ranking note: The highest TxGNN-scored prediction (rank 1) is acromesomelic dysplasia, Hunter-Thompson type (score 99.99%), a rare genetic skeletal disorder with no mechanistic connection to COX inhibition and no supporting clinical evidence. Ankylosing spondylitis (rank 5, score 99.98%) is featured here as the most clinically actionable and biologically plausible prediction.

Quick Overview

Item	Content
Original Indication	None on record (no US NDA found)
Predicted New Indication	Ankylosing Spondylitis
TxGNN Prediction Score	99.98% (overall rank #856 among all drug–disease pairs)
Evidence Level	L3
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Research Question

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data was not retrieved from the available sources. Based on known pharmacological information, diflunisal belongs to the NSAID class as a difluorophenyl salicylate. Its anti-inflammatory and analgesic activity is mediated through inhibition of cyclooxygenase (COX-1 and COX-2) enzymes, which reduces prostaglandin E₂ (PGE₂) synthesis — the central mediator of joint inflammation and pain.

Ankylosing spondylitis (AS) is a chronic inflammatory arthritis of the axial skeleton, strongly associated with HLA-B27, characterized by elevated PGE₂ and other inflammatory mediators driving spinal enthesitis and progressive ankylosis. NSAIDs are the universally recognized first-line pharmacological treatment for AS: by suppressing PGE₂ production, they reduce axial pain, morning stiffness, and inflammatory load. The mechanistic rationale for diflunisal in AS is therefore direct and class-consistent.

Critically, this is not merely a class inference. A 12-week double-blind randomized controlled trial (PMID 3524970) and a 48-week prospective cohort study (PMID 4062389) both directly enrolled AS patients receiving diflunisal — demonstrating that diflunisal improved AS symptom severity comparable to phenylbutazone, with diflunisal showing a more rapid analgesic response. This body of work, though dated, provides stronger direct biological justification than most drug repurposing candidates at equivalent TxGNN score levels.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
3524970	1986	Controlled comparative trial	Clinical Rheumatology	12-week double-blind RCT + 36-week open extension in 38 AS patients: diflunisal 500 mg BID vs phenylbutazone 200 mg BID; both effective, diflunisal showed more pronounced and rapid analgesic onset
4062389	1985	Prospective cohort	Annals of the Rheumatic Diseases	48-week longitudinal study in 38 AS patients on diflunisal or phenylbutazone; serum IgA correlated with disease activity markers including chest expansion and lumbar flexion index
3546687	1986	Cross-sectional study	The Journal of Rheumatology	Spirometric evaluation in 33 AS patients treated with diflunisal or phenylbutazone over 48 weeks; assessed NSAID impact on restrictive pulmonary function impairment caused by thoracic ankylosis
2670397	1989	Drug review	Clinical Pharmacy	Review of diclofenac sodium pharmacology and clinical efficacy in rheumatic diseases including AS; contextual NSAID class evidence
6772422	1980	Drug review	Drugs	Comprehensive review of diclofenac for AS, rheumatoid arthritis, and pain; 75–150 mg/day comparable to aspirin and indomethacin in rheumatic conditions
387372	1979	Drug review	Drugs	Review of naproxen efficacy in rheumatic diseases; establishes propionic acid derivatives as preferred NSAID class — relevant comparative context for salicylate-class diflunisal
3539573	1986	Drug review	Drugs	Review of pirprofen as NSAID for AS, rheumatoid arthritis, and musculoskeletal disorders; contextual NSAID class comparison

Note: PMIDs 2670397, 6772422, 387372, and 3539573 concern other NSAIDs (diclofenac, naproxen, pirprofen), not diflunisal directly. They provide class-level context. The three direct diflunisal-in-AS studies are PMIDs 3524970, 4062389, and 3546687.

US Market Information

No US NDA records found for diflunisal. The drug is currently not marketed in the United States.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Research Question

Rationale: Diflunisal has L3-level evidence for ankylosing spondylitis — including a direct double-blind comparative trial enrolling 38 AS patients — and its COX-inhibitor mechanism aligns precisely with the established NSAID standard of care for AS. However, the evidence base is dated (1980s), no modern RCT or placebo-controlled trial exists, and diflunisal currently holds no US market approval, creating a high evidence-gap risk before any advancement.

To proceed, the following is needed:

Retrieve MOA data from DrugBank (DG002): Formal mechanism-of-action documentation to support regulatory submissions and mechanistic sections
Retrieve US FDA package insert (DG001): Warnings, contraindications, and full safety labeling required before any S1 safety evaluation
Clarify current global regulatory status: Confirm whether diflunisal retains approval in any jurisdiction (EU, Japan, etc.) and identify the reason for US market absence
Commission a modern systematic review: The existing evidence dates to 1985–1986; a systematic search for any subsequent diflunisal use in spondyloarthropathy or AS is needed
Assess comparative safety profile vs modern NSAIDs in AS: Evaluate GI, cardiovascular, and renal risk relative to currently preferred agents (celecoxib, naproxen, indomethacin) in the AS population
Evaluate commercial viability: Assess IP landscape, manufacturing feasibility, and whether a repositioning development pathway (505(b)(2) or similar) is warranted
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.